



RPG LIFE SCIENCES LIMITED

Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India
Tel: +91-22-25292152-55 ♦ Fax: +91-22-25297423

October 29, 2015

To,

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, 'G' Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051.	BSE Limited Floor 25, P.J. Towers Dalal Street Mumbai 400 001.
--	---

Dear Sirs,

Sub: Unaudited financial results for the quarter and half year ended September 30, 2015

(Scrip Code: RPGLIFE / 532983)

We submit herewith the unaudited financial results along with limited review report of the statutory auditors for the quarter and half year ended September 30, 2015. These results have been reviewed by the Audit Committee and have been approved and taken on record by Board of Directors at its respective meetings held on October 29, 2015.

Kindly take the above on your record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head - Legal & Company Secretary



Encl: As above



RPG LIFE SCIENCES LIMITED

PART I STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2015						(Rs. in lakhs)
Particulars	3 months ended 30.9.2015	3 months ended 30.6.2015	3 months ended 30.9.2014	6 months ended 30.9.2015	6 months ended 30.9.2014	Year ended 31.03.2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income from Operations						
(a) Net Sales/Income from Operations (Net of Excise Duty)	6,720	6,650	5,662	13,370	11,541	23,308
(b) Other Operating Income	121	94	98	215	177	919
Total Income from Operations (Net)	6,841	6,744	5,760	13,585	11,718	24,227
2. Expenses						
(a) Cost of Materials Consumed	1,794	1,311	1,743	3,105	3,269	5,920
(b) Purchases of Stock-in-Trade	882	777	759	1,659	1,275	2,378
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(432)	290	(361)	(142)	(128)	171
(d) Employee Benefits Expense	1,797	1,777	1,892	3,574	3,453	6,866
(e) Depreciation and Amortisation Expense	262	255	300	517	526	1,136
(f) Provision for Doubtful Debts and Advances (Net)	(20)	16	9	(4)	18	(323)
(g) Other Expenses	2,272	2,038	2,121	4,310	3,886	7,798
Total Expenses	6,555	6,464	6,463	13,019	12,299	23,946
3. Profit/(Loss) from Operations before Other Income, Finance Costs and Exceptional Items	286	280	(703)	566	(581)	281
4. Other Income	45	28	26	73	56	91
5. Profit/(Loss) from Ordinary Activities before Finance Costs	331	308	(677)	639	(525)	372
6. Finance Costs	75	94	70	169	112	272
7. Profit/(Loss) from Ordinary Activities before Tax	256	214	(747)	470	(637)	100
8. Tax Expense/(Credit) (including Deferred Tax)	-	-	(8)	-	(14)	-
9. Net Profit/(Loss) for the period	256	214	(739)	470	(623)	100
10. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323
11. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)						11,193
12. Earnings/(Loss) per Share (of Rs. 8 each) (not annualised):						
(a) Basic	1.55	1.29	(4.47)	2.84	(3.77)	0.60
(b) Diluted	1.55	1.29	(4.47)	2.84	(3.77)	0.60

PART II Select Information for the Quarter and Half Year ended 30th September, 2015						
Particulars	3 months ended 30.9.2015	3 months ended 30.6.2015	3 months ended 30.9.2014	6 months ended 30.9.2015	6 months ended 30.9.2014	Year ended 31.3.2015
A PARTICULARS OF SHAREHOLDING						
1. Public Shareholding						
- Number of Shares	54,92,188	54,92,188	63,12,564	54,92,188	63,12,564	55,91,135
- Percentage of Shareholding	33.21	33.21	38.17	33.21	38.17	33.81
2. Promoters and Promoter Group Shareholding						
(a) Pledged/Encumbered						
- Number of Shares	-	-	-	-	-	-
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-	-	-
- Percentage of Shares (as a % of the total Share Capital of the company)	-	-	-	-	-	-
(b) Non-Encumbered						
- Number of Shares	110,43,917	110,43,917	102,23,541	110,43,917	102,23,541	109,44,970
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total Share Capital of the company)	66.79	66.79	61.83	66.79	61.83	66.19

2nd Oct



Regd. Off.: RPG House, 463, Dr. Ambedkar Road, Worli, Mumbai 400024
 Tel: +91-22-24981650 / 66606375 ♦ Fax: +91-22-24970127
 E-mail : info@rpglifesciences.com ♦ Web: www.rpglifesciences.com
 CIN : L24232MH2007PLC169354





RPG LIFE SCIENCES LIMITED

Particulars	3 months ended 30.9.2015
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	2
Disposed of during the quarter	2
Remaining unresolved during the quarter	-

Notes:

1. Standalone Statement of Assets and Liabilities

Particulars	(Rs. in lakhs)	
	As at 30.9.2015	As at 31.3.2015
A EQUITY AND LIABILITIES		
1. Shareholders' Funds		
(a) Share Capital	1,323	1,323
(b) Reserves and Surplus	11,663	11,193
Sub-total - Shareholders' Funds	12,986	12,516
2. Non-Current Liabilities		
(a) Long-term Borrowings	32	32
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long-term Liabilities	263	266
(d) Long-term Provisions	158	158
Sub-total - Non-Current Liabilities	453	456
3. Current Liabilities		
(a) Short-term Borrowings	2,934	3,246
(b) Trade Payables	3,816	2,530
(c) Other Current Liabilities	685	664
(d) Short-term Provisions	118	279
Sub-total - Current Liabilities	7,553	6,719
TOTAL - EQUITY AND LIABILITIES	20,992	19,691
B ASSETS		
1. Non-Current Assets		
(a) Fixed Assets	10,900	10,524
(b) Long-term Loans and Advances	548	557
Sub-total - Non-Current Assets	11,448	11,081
2. Current Assets		
(a) Inventories	3,871	3,448
(b) Trade Receivables	4,538	4,061
(c) Cash and Bank Balances	89	72
(d) Short-term Loans and Advances	1,046	1,029
Sub-total - Current Assets	9,544	8,610
TOTAL - ASSETS	20,992	19,691

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meetings held on 29th October, 2015.
- The results for the quarter ended 30th September, 2015 have been subjected to limited review by the statutory auditors of the Company.
- The Company is exclusively engaged in the pharmaceuticals segment.
- Figures for the prior periods have been regrouped where necessary.



For RPG Life Sciences Limited

CT. Renganathan
Managing Director
Mumbai, 29th October, 2015




Regd. Off.: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India
Tel: +91-22-24981650 / 66606375 • Fax: +91-22-24970127
E-mail : info@rpglifesciences.com • Web: www.rpglifesciences.com
CIN : L24232MH2007PLC169354



The Board of Directors
RPG Life Sciences Limited
RPG House
463, Dr. Annie Besant Road
Worli, Mumbai – 400 030

1. We have reviewed the results of RPG Life Sciences Limited (the "Company") for the quarter ended 30th September, 2015 which are included in the accompanying 'Statement of Standalone Unaudited Results for the quarter and half year ended 30th September, 2015' and the statement of assets and liabilities as on that date (the "Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the Management but have neither been reviewed nor been audited by us. The Statement has been prepared by the Company pursuant to Clause 41 of the Listing Agreement with the Stock Exchanges in India, which has been initialled by us for identification purposes. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. We have only traced the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' in the Statement from the disclosures made by the Management and are, therefore, not expressing a review opinion thereon.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Lovelock & Lewes
Firm Registration Number: 301056E
Chartered Accountants



Sumit Seth
Partner
Membership Number 105869

Mumbai
29th October, 2015